Discovery of Cellular Mechanism of Action of tACPA in Rheumatoid Arthritis
Citryll B.V. founded to accelerate tACPA development
12-Jun-2015 -
ModiQuest B.V announces that it has discovered the cellular mechanism of action of its therapeutic anti-citrullinated protein lead antibodies (tACPA) for the treatment of rheumatoid arthritis (RA) and other diseases. To accelerate tACPA development towards clinical Proof of Concept, facilitate ...
antibodies
inflammatory disease
rheumatoid arthritis